 |
|
|
| |
Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) After ISL Dose Reduction From 0.75 mg: Week 48 Results From an Open-Label Phase 3 Study
|
| |
| |
IDWeek; Atlanta, GA, USA; Oct. 19-22, 2025
Rosie Mngqibisa, MD1; Sheetal Kassim, MD2; Cheryl McDonald, MD3; Mark Bloch, MD4; Eugenie Colin-Benoit, MD5; Christopher Bettacchi, MD6; Margaret Johnson, MD7; Hiroyuki Gatanaga, MD8; Euna Kim, BA9; Uchechukwu Nwoke, MS9; Michelle Fox, MD9; Luisa M. Stamm, MD, PhD9; Mengchun Li, MD9; Wayne Greaves, MD9
1Enhancing Care Foundation, Wentworth Hospital, Durban, South Africa; 2Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa; 3Texas Centers for Infectious Disease Associates, Fort Worth, TX, USA; 4Holdsworth House, Sydney, Australia; 5Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland; 6North Texas Infectious Diseases Consultants, Dallas, TX, USA; 7Royal Free London NHS Foundation Trust, London, UK; 8AIDS Clinical Center, NCGM, Tokyo, Japan;
9Merck & Co., Inc., Rahway, NJ, USA
|
| |
|
|
|
|
|
